Oct 6 (Reuters) – * EISAI AND BIOGEN ANNOUNCE U.S. AVAILABILITY OF LEQEMBI® IQLIK™ (LECANEMAB-IRMB) SUBCUTANEOUS INJECTION MAINTENANCE DOSE FOR TREATMENT OF EARLY ALZHEIMER’S DISEASE Source text:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
London (dpa) - This year’s El Niño is set to be the strongest "in living…
Berlin (dpa) - With colorectal cancer case numbers rising among younger and middle-aged adults, doctors…
Washington (dpa) - Makers of personal and domestic hygiene products are not disclosing their use of…
Paris (dpa) - Authorities in France have issued a warning about tens of thousands of…
Disney executive Bob Iger strolls down Main Street and, 60 minutes later, ends up on…
Los Angeles (tca/dpa) - Next up on the tee box, it's season two of the…